2024 What's Next for Latin America Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market?—Growth Opportunities in 22 Countries--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts, Instrumentation Pipeline, Latest Technologies, Market Barriers and Risks
The report is available in Local PDF, Global PDF, and Data Pack formats (supplier shares, test volumes, sales forecasts). The report is delivered in both Excel and PDF.The report is available by section, market segment, and can be customized to your specific information needs and budget.
This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products for diagnosing genetic diseases, cancer, as well as forensic and paternity/HLA testing during the next five years.
Report Presents
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Market Segmentation Analysis
Market Segmentation Analysis
Five-year test volume and sales forecasts for major applications, including:%li%Forensic Testing%li%Cancer>%li%Paternity Testing/HLA Typing %li%Genetic Diseases >%li%Others
Product/Technology Review
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher/Cepheid
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Diasorin
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujirebio
Grifols
Hologic/Gen-Probe
Illumina
LabCorp/Sequenom
Leica Biosystems/Kreatech
Li-Cor Biosciences
Myriad Genetics
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Shimadzu
Siemens Healthineers
Takara Bio
Tecan Group
Thermo Fisher
Rationale
Genetic Diseases, Cancer, Forensic and Paternity testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.
This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products for diagnosing genetic diseases, cancer, as well as forensic and paternity/HLA testing during the next five years.
Report Presents
- Market shares of leading suppliers
- Business and technological trends in major markets
- Five-year test volume and sales forecasts
- Feature comparison of major analyzers
- Strategic profiles of leading market players and start-up firms developing innovative products
- Specific product and business opportunities for instrument and consumable suppliers.
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Business planning issues and concerns.
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Market Segmentation Analysis
Market Segmentation Analysis
Five-year test volume and sales forecasts for major applications, including:%li%Forensic Testing%li%Cancer>%li%Paternity Testing/HLA Typing %li%Genetic Diseases >%li%Others
Product/Technology Review
- Comparison of major molecular diagnostic analyzers.
- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and target/signal amplification methods.
- Worldwide listings of companies developing new molecular diagnostic technologies and products.
- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher/Cepheid
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Diasorin
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujirebio
Grifols
Hologic/Gen-Probe
Illumina
LabCorp/Sequenom
Leica Biosystems/Kreatech
Li-Cor Biosciences
Myriad Genetics
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Shimadzu
Siemens Healthineers
Takara Bio
Tecan Group
Thermo Fisher
Rationale
Genetic Diseases, Cancer, Forensic and Paternity testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.
I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Review
A. DNA Sequencing
1. INTRODUCTION
2. SEQUENCING METHODS
3. AUTORADIOGRAPHY
4. THE HUMAN GENOME PROJECT
5. SEQUENCING AUTOMATION
6. IMAGE SCANNERS
7. FLUORESCENT DETECTION
8. GENE PROFILING
9. GENE EXPRESSION
10. POLYMORPHISM SCREENING
11. PROTEIN INTERACTION NETWORKS
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Review
A. DNA Sequencing
1. INTRODUCTION
2. SEQUENCING METHODS
3. AUTORADIOGRAPHY
4. THE HUMAN GENOME PROJECT
5. SEQUENCING AUTOMATION
6. IMAGE SCANNERS
7. FLUORESCENT DETECTION
8. GENE PROFILING
9. GENE EXPRESSION
10. POLYMORPHISM SCREENING
11. PROTEIN INTERACTION NETWORKS
